Pipeline

Medigene’s proprietary end-to-end platform enables the development of differentiated, best-in class T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Medigene develops these therapies on its own or in partnership.

  • Discovery Stage
  • CTA/IND-enabling
  • Clinical Studies
Upcoming Milestone

Multiple Solid Tumor Types

NY-ESO-1 + PD1-41BB / HLA-A2

MDG1015

CTA / IND 2H 2024

Medigene’s lead candidate targeting NY-ESO-1 combined with our PD1-41BB costimulatory switch receptor. 

Undisclosed Targets / Undisclosed HLAs + PD1-41BB

MDG10XX

Lead selection 2H 2023

Generation of TCR T cells targeting appropriate antigens with several different HLA types each developed and improved with our optimization technologies and combined with our PD1-41BB costimulatory switch receptor.

PRAME / HLA-A2

Milestones set by BioNtech

Exclusively partnered with BioNtech.  Also includes non-exclusive licenses to our optimization technologies

MAGE-A4 / HLA-A2

Milestones set by 2seventy bio

Exclusively partnered with 2seventy bio.

NY-ESO-1 / HLA-A2

Milestones set by Hongsheng Sciences

Exclusively partnered with Hongsheng Sciences.

Multiple Liquid Tumor Types

PRAME / HLA-A2

MDG1011

NY-ESO-1 / HLA-A2

Milestones set by Hongsheng Sciences

Exclusively partnered with Hongsheng Sciences.

Medigene’s Own Programs with Multiple Value Inflection Points

Program
Target
Product Enhancement
  • Discovery
  • Lead Candidate
  • CTA/IND-enabling
  • Clinical Studies
Next Milestone

MDG1015

NY-ESO-1 / LAGE-1a

PD1-41BB

HLA-A2

CTA / IND 2H 2024

Medigene’s lead candidate targeting NY-ESO-1 combined with our PD1-41BB costimulatory switch receptor. 

MDG2011

KRAS G12V

PD1-41BB / CD40L-CD28

HLA-A11

Lead selection Q3 2023

MDG2021

KRAS G12D

PD1-41BB / CD40L-CD28

HLA-A11

Lead selection 1H 2024

MDG2012

KRAS G12V

PD1-41BB / CD40L-CD28

HLA-A3

Lead selection 2024

MDG20XX

KRAS

PD1-41BB / CD40L-CD28

TBD

Medigene exploring additional multiple HLAs.

MDG10XX

undisclosed

undisclosed

TBD

Generation of TCR T cells targeting appropriate antigens with several different HLA types each developed and improved with our optimization technologies.

Multiple Partnerships Validate Potential Best-in-Class TCRs

Program
Target
Optimizations
  • Discovery
  • Lead Candidate
  • CTA/IND-enabling
  • Clinical Studies
Next Milestone

PRAME

Yes

HLA-A2

Set by BioNTech

Exclusively partnered with BioNtech.  Also includes non-exclusive licenses to our optimization technologies

MAGE-A4

Yes*

HLA-A2

Set by 2seventybio

Exclusively partnered with 2seventy bio.

NY-ESO-1

Yes

HLA-A2

Set by Hongsheng Sciences

Exclusively partnered with Hongsheng Sciences.

MDG1011

PRAME

No

HLA-A2

Partnering

NY-ESO-1

No

HLA-A2

Set by Hongsheng Sciences

Exclusively partnered with Hongsheng Sciences.

* Enhancement not licensed from Medigene

INTELLECTUAL PROPERTY

Medigene’s proprietary end-to-end platform for identifying, selecting and engineering best-in-class TCRs is protected by exclusively in-licensed and proprietary patents in Europe, North America and Japan. Patent rights individually protect all TCRs generated by our proprietary TCR platform technology in countries selected based on our corporate commercial long-term strategy. In addition, Medigene is constantly developing improved methods and technologies across our end-to-end platform to produce the best TCR therapies. These methods are also subject to new patent protection in line with our company’s patent strategy.